What Bradykinin is
Bradykinin is an endogenous vasoactive peptide involved in vasodilation, inflammatory signaling, and pain physiology.
Bradykinin is grouped under Endogenous / Biology on PeptideFactCheck because it helps explain inflammatory and vascular peptide signaling in a more fundamental way than product-focused profiles alone.
The useful starting point is to separate the molecule itself from the internet story around it. It helps explain inflammatory and vascular peptide signaling in a more fundamental way than product-focused profiles alone.
Why people keep looking it up
It helps explain inflammatory and vascular peptide signaling in a more fundamental way than product-focused profiles alone.
Bradykinin is an endogenous vasoactive peptide involved in vasodilation, inflammatory signaling, and pain physiology.
Bradykinin tends to stay in the conversation because it touches a familiar public theme: vasoactive peptide, inflammation, and pain signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Core vasoactive peptide biology with strong human relevance.
Human physiology is well established, though this is mostly a reference-biology entry.
Mechanistic support is extensive across vascular and inflammatory research.
Why this page carries the current tier: Core vasoactive peptide biology with strong human relevance.
The current seed trail for Bradykinin is pulling from 2 databases sources and 1 literature source.
Safety, limits, and regulatory context
Its relevance is real, but it is not a casual consumer peptide category.
Bradykinin is tracked here as endogenous biology.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Bradykinin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Bradykinin is CID 439201. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 439201
- Formula
- C50H73N15O11
- Molecular weight
- 1060.2
- InChIKey
- QXZGBUJJYSLZLT-FDISYFBBSA-N
Matched synonyms include BRADYKININ, 58-82-2, L-Bradykinin, Kallidin I, Callidin I, Kallidin-9, (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid, BRS-640.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Bradykinin returns 71 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Bradykinin returns 22829 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.